亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial

医学 超重 赛马鲁肽 体质指数 2型糖尿病 人口 安慰剂 肥胖 减肥 内科学 物理疗法 糖尿病 内分泌学 环境卫生 利拉鲁肽 替代医学 病理
作者
Takashi Kadowaki,Line Dam Heftdal,Hae‐Jin Ko,Maria Overvad,Iichiro Shimomura,Usha K. Thamattoor,Kyoung Kon Kim,OASIS 2 Investigators,Hideyuki Kunishige,Jun Okude,Naoki Sato,Satoshi Takeda,Koji Uemura,Takeshi Osonoi,Satomi Isshiki,Naoaki Ito,Hitoshi Naito,Norihiko Oka,Mitsuru Hosoya,Miyoko Saito
出处
期刊:JAMA Internal Medicine [American Medical Association]
卷期号:185 (10): 1206-1206 被引量:33
标识
DOI:10.1001/jamainternmed.2025.3599
摘要

Importance: The efficacy and safety of oral semaglutide, 50 mg, in an East Asian population that also includes individuals with type 2 diabetes (T2D), who are prone to weight-related complications at lower body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) thresholds than other ethnic groups, is currently unknown. Objective: To assess the efficacy and safety of once-daily oral semaglutide, 50 mg, for the treatment of overweight and obesity in East Asian individuals with or without T2D. Design, Setting, and Participants: The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea. Adults with a BMI of 27.0 or greater with 2 or more related complications or a BMI of 35.0 or greater with 1 or more related complications were enrolled. Approximately 25% of participants were planned to have T2D at screening. Data were analyzed from March 2022 to July 2025. Interventions: Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks. Main Outcomes and Measures: The coprimary end points were percentage change in body weight from baseline and the proportion of participants who achieved 5% or greater body weight reductions. Changes in physical function, cardiometabolic risk factors, and safety were also evaluated. Results: Overall, 201 participants (mean [SD] age, 49 [11] years; mean [SD] body weight, 91.9 [18.2] kg; 87 [43.3%] female; 51 [25.4%] with T2D) were randomized to semaglutide (n = 134) or placebo (n = 67). The mean (SEM) percentage change in body weight was -14.3% (0.8) with semaglutide vs -1.3% (1.1) with placebo (estimated treatment difference, -13.07 percentage points; 95% CI, -15.61 to -10.52; P < .001). More participants had 5% or greater body weight reductions with semaglutide vs placebo (107 of 127 [84.3%] vs 11 of 64 [17.2%]; odds ratio, 23.00; 95% CI, 10.28-51.42; P < .001). Gastrointestinal tract adverse events were reported by 85 of 134 participants (63.4%) with semaglutide and 23 of 66 with placebo (34.8%). Adverse events led to treatment discontinuation in 6 of 134 participants (4.5%) in the semaglutide arm. Conclusions and Relevance: In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without T2D, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction in body weight compared with placebo, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist class. Trial Registration: ClinicalTrials.gov Identifier: NCT05132088.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
小野发布了新的文献求助10
9秒前
14秒前
null的应助被浮云采纳,获得10
16秒前
19秒前
符聪发布了新的文献求助10
20秒前
佳佳发布了新的文献求助10
25秒前
40秒前
Shicheng完成签到,获得积分10
1分钟前
1分钟前
1分钟前
hu发布了新的文献求助10
1分钟前
童严柯发布了新的文献求助10
1分钟前
1分钟前
1分钟前
zsmj23完成签到 ,获得积分0
1分钟前
RONG发布了新的文献求助80
1分钟前
1分钟前
童严柯完成签到,获得积分10
1分钟前
飞快的兔子完成签到,获得积分10
1分钟前
无情棒棒糖完成签到 ,获得积分10
1分钟前
佳佳发布了新的文献求助10
2分钟前
2分钟前
2分钟前
NexusExplorer的应助被ww采纳,获得10
2分钟前
Wendyyolo发布了新的文献求助10
2分钟前
2分钟前
2分钟前
佳佳发布了新的文献求助20
2分钟前
ww发布了新的文献求助10
2分钟前
Wendyyolo完成签到 ,获得积分10
2分钟前
浮云发布了新的文献求助10
2分钟前
土狗望月完成签到,获得积分10
3分钟前
呋喃完成签到,获得积分10
3分钟前
Lan完成签到 ,获得积分10
3分钟前
3分钟前
ww发布了新的文献求助10
3分钟前
SciGPT的应助被符聪采纳,获得10
3分钟前
zzz完成签到,获得积分10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195136
求助须知:如何正确求助?哪些是违规求助? 9580891
关于积分的说明 21872912
捐赠科研通 7795116
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561241
邀请新用户注册赠送积分活动 2484609